Trials / Completed
CompletedNCT07354282
Real World Evidence of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma
Retrospective, Multicenter, Real-world Observational Study of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- Spanish Oncology Genito-Urinary Group · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The SOGUG-TIVOREAL study is a retrospective observational study with medications. This study is based on the retrospective collection of data from patients who have been treated with Tivozanib as first-line therapy between 03/01/2019 and 08/31/2024 for metastatic renal cell carcinoma (mRCC).
Conditions
Timeline
- Start date
- 2025-05-13
- Primary completion
- 2025-08-07
- Completion
- 2025-08-07
- First posted
- 2026-01-21
- Last updated
- 2026-01-21
Locations
14 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT07354282. Inclusion in this directory is not an endorsement.